Ali Vazir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ali Vazir has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Martin Cowie
Imperial College London, London, UK
3 shared publications - Aditya Bhalla
Department of Cardiology, Guy’s and St Thomas’ NHS Trust, London, UK
1 shared publication Ajay M. Shah
King's College Hospital NHS Foundation Trust, London, United Kingdom
1 shared publicationAlastair Gray
Craigavon Cardiac Centre, Craigavon Area Hospital, Craigavon, United Kingdom
1 shared publication- Andrew Flett
Department of Cardiology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
1 shared publication Andrew Ludman
Department of Cardiology, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 23 May 2025
- Published by Radcliffe Medical Media Ltd in Interventional Cardiology: Reviews, Research, Resources
- Vol. 20, e18
Sex Differences in Heart Failure: A Step Forward
Heart failure is a life-threatening condition that affects women and men differently. Due to increases in mean patient age, heart failure prevalence and mortality rates are expected to increase rapidly. Heart failure is characterised as a syndrome leading to a high burden of disease for the individual patient and increased healthcare costs for society related to rehospitalisation. This review highlights sex differences across the entire spectrum of heart failure.
- 23 May 2025
- Published by Radcliffe Medical Media Ltd in Interventional Cardiology: Reviews, Research, Resources
- Vol. 20, e18
Open AccessSex Differences in Heart Failure: A Step Forward
Heart failure is a life-threatening condition that affects women and men differently. Due to increases in mean patient age, heart failure prevalence and mortality rates are expected to increase rapidly. Heart failure is characterised as a syndrome leading to a high burden of disease for the individual patient and increased healthcare costs for society related to rehospitalisation. This review highlights sex differences across the entire spectrum of heart failure.
- Open Access
- 9 April 2025
- Published by Elsevier in JACC: Heart Failure
- Vol. 13 (6) , 1000-1010
First-in-Human Implantable Inferior Vena Cava Sensor for Remote Care in Heart Failure
- 9 April 2025
- Published by Elsevier in JACC: Heart Failure
- Vol. 13 (6) , 1000-1010
Open AccessFirst-in-Human Implantable Inferior Vena Cava Sensor for Remote Care in Heart Failure
- Open Access
- 2 July 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (8) , 101064
Race- and Ethnicity-Related Differences in Heart Failure With Preserved Ejection Fraction Using Natural Language Processing
- 2 July 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (8) , 101064
Open AccessRace- and Ethnicity-Related Differences in Heart Failure With Preserved Ejection Fraction Using Natural Language Processing
- Open Access
- 1 November 2023
- Published by Elsevier in JACC: Case Reports
- Vol. 25, 102059
Time to Redefine Optimal Medical Therapy With Contemporary Therapies for Secondary Tricuspid Valve Regurgitation
- 1 November 2023
- Published by Elsevier in JACC: Case Reports
- Vol. 25, 102059
Open AccessTime to Redefine Optimal Medical Therapy With Contemporary Therapies for Secondary Tricuspid Valve Regurgitation
Sleep-disordered breathing and cardiovascular disease: who and why to test and how to intervene?
Sleep-disordered breathing (SDB) is common in individuals with established cardiovascular disease (CVD), particularly those with heart failure (HF). There are two main types of SDB, central sleep apnoea (CSA) and obstructive sleep apnoea (OSA) which frequently overlap as mixed SDB. Investigating for SDB could be considered in patients with excessive daytime sleepiness, male sex, high body mass index, low ejection fraction, atrial fibrillation (AF), in patients with no dipping blood pressure pattern, recurrent paroxysms of nocturnal dyspnoea or when an apnoea is witnessed. Excessive daytime sleepiness is less likely to be reported by patients with HF than by the general population. In patients with CVD and OSA, continuous positive airway pressure (CPAP) ventilation for over 4 hours daily reduced the risk of major adverse cardiovascular events, but there was no reduction in mortality. In patients with AF and OSA treated with AF ablation, CPAP use was associated with a reduced risk of recurrence of AF. In patients with HF and OSA, small studies have demonstrated that CPAP improves symptoms, brain natriuretic peptide levels and ejection fraction, but data on survival are lacking. Treatment remains unclear in patients with HF and CSA. The presence of CSA may be a defensive adaptive response to HF, and effectively treating CSA as demonstrated in a randomised clinical trial of adaptive servo-ventilation caused more harm than benefit when compared to optimal medical therapy. Thus, the focus of treating CSA should remain on improving the underlying HF by optimising medical therapy and, if indicated, cardiac resynchronisation therapy.
Sleep-disordered breathing and cardiovascular disease: who and why to test and how to intervene?
Sleep-disordered breathing (SDB) is common in individuals with established cardiovascular disease (CVD), particularly those with heart failure (HF). There are two main types of SDB, central sleep apnoea (CSA) and obstructive sleep apnoea (OSA) which frequently overlap as mixed SDB. Investigating for SDB could be considered in patients with excessive daytime sleepiness, male sex, high body mass index, low ejection fraction, atrial fibrillation (AF), in patients with no dipping blood pressure pattern, recurrent paroxysms of nocturnal dyspnoea or when an apnoea is witnessed. Excessive daytime sleepiness is less likely to be reported by patients with HF than by the general population. In patients with CVD and OSA, continuous positive airway pressure (CPAP) ventilation for over 4 hours daily reduced the risk of major adverse cardiovascular events, but there was no reduction in mortality. In patients with AF and OSA treated with AF ablation, CPAP use was associated with a reduced risk of recurrence of AF. In patients with HF and OSA, small studies have demonstrated that CPAP improves symptoms, brain natriuretic peptide levels and ejection fraction, but data on survival are lacking. Treatment remains unclear in patients with HF and CSA. The presence of CSA may be a defensive adaptive response to HF, and effectively treating CSA as demonstrated in a randomised clinical trial of adaptive servo-ventilation caused more harm than benefit when compared to optimal medical therapy. Thus, the focus of treating CSA should remain on improving the underlying HF by optimising medical therapy and, if indicated, cardiac resynchronisation therapy.
- 1 February 2020
- Published by Elsevier in International Journal of Cardiology
- Vol. 300, 237-244
Impact on survival of combination inhalers in patients with COPD at high risk of cardiovascular events
- 1 February 2020
- Published by Elsevier in International Journal of Cardiology
- Vol. 300, 237-244
Impact on survival of combination inhalers in patients with COPD at high risk of cardiovascular events
- Open Access
- 1 August 2019
- Published by Elsevier in JACC: Case Reports
- Vol. 1 (2) , 166-167
Stress-Induced Shock
- 1 August 2019
- Published by Elsevier in JACC: Case Reports
- Vol. 1 (2) , 166-167
Open AccessStress-Induced Shock
- 1 October 2018
- Published by Elsevier in Heart Failure Clinics
- Vol. 14 (4) , 635-642
Management of Sleep Apnea in Heart Failure
- 1 October 2018
- Published by Elsevier in Heart Failure Clinics
- Vol. 14 (4) , 635-642
Management of Sleep Apnea in Heart Failure